XML 16 R112.htm IDEA: XBRL DOCUMENT v2.4.0.8
Business Segment and Geographic Information (Information About Reportable Segments) (Detail) (USD $)
In Thousands, unless otherwise specified
3 Months Ended 12 Months Ended
Dec. 31, 2013
Sep. 30, 2013
Jun. 30, 2013
Mar. 31, 2013
Dec. 31, 2012
Sep. 30, 2012
Jun. 30, 2012
Mar. 31, 2012
Dec. 31, 2013
Dec. 31, 2012
Dec. 31, 2011
Segment Reporting Information [Line Items]                      
Net sales $ 136,231 $ 142,820 $ 132,452 $ 125,979 $ 124,176 $ 129,134 $ 125,296 $ 120,155 $ 537,482 [1] $ 498,761 [1] $ 548,341 [1]
Operating income (loss)                 49,280 25,664 53,482
Total assets 806,534       760,024       806,534 760,024  
Capital expenditures                 16,859 23,774 21,316
Depreciation & amortization                 26,351 27,130 26,308
Investment in unconsolidated joint ventures 18,463       21,171       18,463 21,171  
Equity income in unconsolidated joint ventures                 4,326 4,743 5,451
Operating Segments [Member]
                     
Segment Reporting Information [Line Items]                      
Net sales                 537,482 498,761 548,341
Operating income (loss)                 49,280 25,664 53,482
Total assets 806,534       759,278       806,534 759,278 676,785
Capital expenditures                 16,859 23,774 21,316
Depreciation & amortization                 26,351 27,130 26,308
Investment in unconsolidated joint ventures 18,463       21,171       18,463 21,171 23,868
Equity income in unconsolidated joint ventures                 4,326 4,743 5,451
Operating Segments [Member] | High Performance Foams [Member] | Reportable Segment [Member]
                     
Segment Reporting Information [Line Items]                      
Net sales                 168,082 179,421 177,645
Operating income (loss)                 22,339 25,730 28,280
Total assets 221,848       233,401       221,848 233,401 192,829
Capital expenditures                 3,030 4,947 5,325
Depreciation & amortization                 6,410 7,947 7,873
Investment in unconsolidated joint ventures 18,463       21,171       18,463 21,171 23,868
Equity income in unconsolidated joint ventures                 4,326 4,743 5,451
Operating Segments [Member] | Printed Circuit Materials [Member] | Reportable Segment [Member]
                     
Segment Reporting Information [Line Items]                      
Net sales                 184,949 161,893 166,424
Operating income (loss)                 18,788 8,170 11,127
Total assets 177,716       156,103       177,716 156,103 123,883
Capital expenditures                 7,793 12,849 5,901
Depreciation & amortization                 7,004 7,172 6,348
Investment in unconsolidated joint ventures                           
Equity income in unconsolidated joint ventures                         
Operating Segments [Member] | Power Electronics Solutions [Member] | Reportable Segment [Member]
                     
Segment Reporting Information [Line Items]                      
Net sales                 160,730 134,279 180,234
Operating income (loss)                 1,088 (12,022) 11,320
Total assets 382,818       345,013       382,818 345,013 338,418
Capital expenditures                 5,287 5,746 9,362
Depreciation & amortization                 12,406 11,083 10,989
Investment in unconsolidated joint ventures 0       0       0 0 0
Equity income in unconsolidated joint ventures                 0 0 0
Operating Segments [Member] | Other [Member] | Reportable Segment [Member]
                     
Segment Reporting Information [Line Items]                      
Net sales                 23,721 23,168 24,038
Operating income (loss)                 7,065 3,786 2,755
Total assets 24,152       24,761       24,152 24,761 21,655
Capital expenditures                 749 232 728
Depreciation & amortization                 531 928 1,098
Investment in unconsolidated joint ventures                           
Equity income in unconsolidated joint ventures                         
[1] Net sales are allocated to countries based on the location of the customer.